Mr. Nicholas Kadysh reports

PHARMALA BEGINS TRADING ON OTCQB

Pharmala Biotech Holdings Inc. has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. and the company's common shares commenced trading today on the OTCQB under the symbol PMBHF. Pharmala's common shares will continue to trade on the Canadian Securities Exchange (CSE) under the ticker MDMA.

"This listing is the result of an exceedingly long process, which I'm pleased we've finally completed," stated Nick Kadysh, chief executive officer, Pharmala Biotech. "We believe that this move will open the doors to greater access and trading capability in our shares for both institutional and retail investors; this is just one part of our continued efforts to grow the Pharmala story."

Pharmala's OTC listing, which will allow for greater access to its stock for United States investors, follows the company's receipt earlier this year of regulatory allowances from the U.S. Food and Drug Administration (USFDA) for its LaNeo MDMA to be used in U.S. clinical trials. The OTCQB offers investors transparent trading in entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

About Pharmala Biotech Holdings Inc.

Pharmala is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules, including MDMA (3,4-methylenedioxymethamphetamine). Pharmala was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. Pharmala is the first publicly traded company to manufacture clinical-grade MDMA. Pharmala's research and development unit has completed proof-of-concept research into ALA-002, Pharmala's lead drug candidate. Pharmala is a regulatory-first organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

We seek Safe Harbor.